ALECTOR INC. - COMMON STOCK

Alector Secures Flexible Credit Facility for Up to $50 Million From Hercules Capital

14 Nov 2024 15:05:46 By Nasdaq GlobeNewswire

Alector Reports Third Quarter 2024 Financial Results and Provides Business Update

06 Nov 2024 15:05:00 By Nasdaq GlobeNewswire

Alector Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024)

19 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

Alector to Participate in Upcoming Healthcare Conferences

29 Aug 2024 06:00:00 By Nasdaq GlobeNewswire

Alector Reports Second Quarter 2024 Financial Results and Provides Business Update

07 Aug 2024 15:05:00 By Nasdaq GlobeNewswire

Alector to Host Mid-Year Earnings Conference Call

31 Jul 2024 15:05:00 By Nasdaq GlobeNewswire

Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)

28 Jul 2024 07:05:00 By Nasdaq GlobeNewswire

Alector to Present Data on Pipeline Focus Areas at the Alzheimer's Association International Conference® (AAIC®) 2024

23 Jul 2024 06:00:00 By Nasdaq GlobeNewswire

Alector to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

20 Jun 2024 06:00:00 By Nasdaq GlobeNewswire

Alector to Host Virtual Research and Development Event Highlighting Alector Brain Carrier Blood-Brain Barrier Technology Platform

10 Jun 2024 06:00:00 By Nasdaq GlobeNewswire

Alector to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

03 Jun 2024 06:00:00 By Nasdaq GlobeNewswire

Alector to Participate in Upcoming Healthcare Conferences

09 May 2024 06:00:00 By Nasdaq GlobeNewswire

Alector Reports First Quarter 2024 Financial Results and Provides Business Update

08 May 2024 15:05:01 By Nasdaq GlobeNewswire

Alector to Participate in Upcoming Healthcare Conferences

28 Feb 2024 06:00:00 By Nasdaq GlobeNewswire

Alector Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

27 Feb 2024 15:05:00 By Nasdaq GlobeNewswire

Alector to Host Fourth Quarter and Full-Year 2023 Earnings Call

20 Feb 2024 15:05:00 By Nasdaq GlobeNewswire

Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer’s Disease

08 Feb 2024 06:00:00 By Nasdaq GlobeNewswire

FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)

07 Feb 2024 06:00:00 By Nasdaq GlobeNewswire

Alector Announces Closing of Public Offering

19 Jan 2024 08:20:36 By Nasdaq GlobeNewswire

Alector Announces Pricing of Public Offering of Common Stock

17 Jan 2024 07:54:32 By Nasdaq GlobeNewswire